COVID-19 and psoriasis: biologic treatment and challenges

Ebrahimi, Aziz; Sayad, Babak; Rahimi, Zohreh

doi:10.1080/09546634.2020.1789051

Cited by 36 publications

(38 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the particular case of COVID-19, as mentioned above, there is little data of real risk of infection in NMD patients. However, several cohorts of patients with autoimmune diseases such as psoriasis, rheumatoid arthritis, multiple sclerosis, or optic neuromyelitis show that treatment with immunosuppressants does not increase the risk of suffering from COVID-19 and neither present a more severe form of infection (25)(26)(27)(28).…”

Section: Treatmentmentioning

confidence: 99%

Neuromuscular Diseases Care in the Era of COVID-19

Recasens

Rubio

2020

Front. Neurol.

View full text Add to dashboard Cite

The COVID-19 pandemic has pushed health systems to their limit and forced readjustment of standards of care for different pathologies. Management of neuromuscular diseases becomes a challenge since most of them are chronic, disabling, progressive, and/or require immunosuppressive drugs. There are three main aspects of COVID-19 that affect neuromuscular diseases care. The first one relates to how SARS-CoV2 directly affects different neuromuscular pathologies. Respiratory weakness, as seen in myasthenia gravis, amyotrophic lateral sclerosis, and myopathies, and the use of immunomodulatory drugs (Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy) make this group of patients potentially more vulnerable. Secondly, safety measures also affect proper care, limiting care continuity, and physical rehabilitation (one of the essential aspects of myopathies treatment). Telemedicine can partially solve the problem allowing for a continuum of close care, avoiding unnecessary visits, and even guaranteeing the attention of professionals from tertiary care centers. However, one of the crucial steps in neuromuscular diseases is diagnosis, and in most scenarios, more than one face-to-face visit is needed. Lastly, the global COVID-19 situation will also have an economic impact on patients and their families. This situation is of particular concern given that neuromuscular diseases already present difficulties due to the scarcity of resources in terms of public healthcare and research.

show abstract

Section: Treatmentmentioning

confidence: 99%

Neuromuscular Diseases Care in the Era of COVID-19

Recasens

Rubio

2020

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Moreover, it is complicated with thrombotic complications (1). In response to COVID-19 infection, activation of T cells along with massive production and release of cytokines occur with subsequent damage to internal organs, and primarily the lungs (2). Around 40% of hospitalized patients with COVID-19 are at a high risk of development of venous thromboembolism (VTE) (3).…”

Section: Introductionmentioning

confidence: 99%

Blood coagulation parameters in patients with severe COVID-19 from Kermanshah Province, Islamic Republic of Iran

Sayad¹,

Rahimi²

2020

East Mediterr Health J.

Self Cite

View full text Add to dashboard Cite

Background: Infection with coronavirus disease 2019 (COVID-19) could be complicated with coagulopathy and high risk of thromboembolic events. Aims: The main aim of the present study was to find the coagulation profile of intensive care unit (ICU) admitted patients with COVID-19 from Kermanshah, Islamic Republic of Iran. Methods: Coagulation parameters were analyzed using appropriate methods in 74 patients (24 patients aged <60 years and 50 patients ≥60 years) and were compared with 35 survivors (severe COVID-19) and 39 non-survivors (severe COVID-19) historically admitted to the ICU. Results: Forty-two percent of patients had abnormal prothrombin time and international normalized ratio. The rates of mortality and comorbidity in patients aged ≥ 60 years were 73.7% and 78.4% compared to 26.3% and 21.6%, respectively, in patients aged < 60 years. Conclusion: We found an abnormal pattern of coagulation parameters and association of advanced age and comorbidities with a high rate of mortality in severe COVID-19 patients, which should be taken into consideration in their hospital management.

show abstract

“…Like our colleagues around the world, we soon adopted the policy to continue anti–tumor necrosis factor agents for our patients with psoriasis and hidradenitis suppurativa, the two main indications of this class of drugs, unless they had been infected with COVID-19. 99 , 100 For psoriatic patients with no evidence of arthritis, acitretin is becoming more popular, and phototherapy, although well tolerated, is suggested with caution considering the need for thrice-weekly commutes. Cyclosporine and methotrexate are used with more caution, and in the case of COVID-19, their use is suspended until complete recovery from the infection.…”

Section: New Challengesmentioning

confidence: 99%